Function Oncology to Present New Data from CRISPR-Powered Personalized Functional Genomics Platform at the American Association for Cancer Research (AACR) 2023 Annual Meeting

On April 12, 2023 Function Oncology, a company transforming the future of targeted cancer treatment with a CRISPR-powered precision medicine platform, reported an upcoming presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2023 Annual Meeting (Press release, Function Oncology, APR 12, 2023, View Source [SID1234630027]). The presentation will feature data from an acute myeloid leukemia (AML) cohort that demonstrate the power of Function Oncology’s CRISPR-based personalized functional genomics platform to profile and understand cancer in unprecedented and patient-specific detail.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data underscore the powerful potential of our functional genomics platform to produce tailored treatment strategies," said Srihari Sampath, M.D., Ph.D., MPhil, co-founder and chief scientific officer. "In this study, our platform achieved very high sensitivity and specificity to identify gene dependencies driving individual patient responses, as well as high predictive value for observed clinical outcomes. For the first time, we are able to efficiently move beyond traditional gene sequencing to directly measuring gene function in order to define optimal therapeutic strategies for cancer patients."

Details of the presentation are as follows:
Title: A comprehensive CRISPR-enabled functional genomics profiling platform in Acute
Myeloid Leukemia (AML): pilot study and validation of Fx Heme
Format: Poster presentation
Abstract Number: 1062
Session Title: Session PO.CL09.03 – Precision Molecular Subtyping and Therapeutic Development
Date and Time: Sunday, April 16, 2023, 1:30 PM – 5:00 PM ET